Aldosterone antagonists may be of benefit post-STEMI

Clinical Question

In patients with ST-elevated myocardial infarction with preserved left ventricular function, is adding an aldosterone antagonist to usual therapy effective in delaying mortality?

Bottom line

Aldosterone antagonists—spironolactone, eplerenone (Inspra), and canrenoate (Venactone, Soldactone; not available in the United States)—given acutely may have a benefit on delaying mortality in patients with ST-elevated myocardial infarction (STEMI), even in patients with preserved left ventricular function. The effect may be pronounced or quite minor, with a number needed to treat estimate ranging from 45 to 295, and we can use more studies of longer treatment. Available evidence does not show a benefit on the development of heart failure, myocardial infarction, or ventricular arrhythmia. 1a-

Study design: Meta-analysis (randomized controlled trials)

Funding: Unknown/not stated

Setting: Inpatient (any location)

Reviewer

Allen F. Shaughnessy, PharmD, MMedEd
Professor of Family Medicine
Tufts University
Boston, MA


Discuss this POEM


Comments

Anonymous

The blurb at the top of this info poem says the NNT is 45 to 295. The content of the info poem says the confidence interval is 45 to 295. These are surely not the identical same numbers! Poor editing, Info Poems!?

Anonymous

Good poem